US Patent 12,076,323: Deuruxolitinib Alopecia Areata Patent Scope and Exclusivity Analysis

US Patent No. 12,076,323 protects the use of deuterated ruxolitinib, commercially known as deuruxolitinib, for treating hair-loss disorders at a total daily dose of 16 mg. Its most commercially important claims cover oral phosphate-salt administration of 8 mg twice daily for alopecia areata, including tablet formulations with at least 95% or 97% deuterium incorporation.

The patent is assigned to Concert Pharmaceuticals, Inc., whose deuruxolitinib program was acquired by Sun Pharmaceutical Industries. The product is marketed in the United States as Leqselvi for severe alopecia areata in adults and adolescents 12 years and older.[1]

What drug and product does US Patent 12,076,323 cover?

The claimed compound is the deuterated JAK inhibitor deuruxolitinib, formerly CTP-543. It is a deuterium-modified form of ruxolitinib designed to alter metabolic behavior while retaining JAK1/JAK2 inhibitory activity.

The claims identify the compound by structural formula rather than by the generic name. The covered product is the phosphate salt of deuruxolitinib used in Leqselvi tablets.

Attribute	Patent scope
Active compound	Deuterated ruxolitinib, deuruxolitinib
Commercial product	Leqselvi
Marketing company	Sun Pharmaceutical Industries
Original developer	Concert Pharmaceuticals
Primary indication	Alopecia areata
Dose	16 mg per day
Key commercial regimen	8 mg orally twice daily
Salt	Phosphate salt
Dosage form	Tablet
Deuterium purity	At least 95%; selected claims require at least 97%
Patient population	Human subjects
Claim type	Method-of-treatment claims

The patent does not principally claim the molecule as a composition of matter. Its central protection is therapeutic use at a specified dose and in a specified clinical setting.

What do the independent claims protect?

The patent has two principal independent claims.

Claim 1: broad 16 mg-per-day hair-loss treatment

Claim 1 covers:

A human subject;
A hair-loss disorder;
Administration of 16 mg per day;
Deuruxolitinib or a pharmaceutically acceptable salt;
At least 95% deuterium incorporation at each position specifically designated as deuterium.

The phrase “hair loss disorder” is broader than alopecia areata. On its face, claim 1 can encompass treatment of other hair-loss conditions if the remaining limitations are met. The claim does not require oral dosing, a tablet, a phosphate salt, or once-daily administration.

This creates several possible dosing implementations:

16 mg once daily;
8 mg twice daily;
Other dosing schedules totaling 16 mg per day, subject to claim construction and proof of infringement.

A product administered at 16 mg per day would not avoid claim 1 merely because it is supplied in a different dosage form or as a different pharmaceutically acceptable salt.

Claim 27: commercially focused alopecia areata claim

Claim 27 is narrower but more directly aligned with Leqselvi. It requires:

Treatment of alopecia areata;
Oral administration;
8 mg twice daily;
A phosphate salt;
At least 95% deuterium incorporation.

This is the patent’s clearest product-facing claim. A generic or follow-on product that copies the Leqselvi regimen and uses the same phosphate salt would face direct infringement exposure if the patent is enforceable and the product is marketed for the claimed use.

How do the dependent claims narrow the patent?

Claims 2 through 26 add dosing, administration, formulation, salt, and deuterium-purity limitations to claim 1 or claim 2. Claims 28 and 29 narrow claim 27.

Claims	Added limitation
2	Alopecia areata
3	Oral administration
4	Tablet formulation
5	Once-daily administration
6	Twice-daily administration
7	8 mg twice daily
8	At least 97% deuterium incorporation
9	Oral phosphate salt
10	Phosphate salt once daily
11	Phosphate salt twice daily
12-14	At least 97% deuterium incorporation plus phosphate salt
15-26	Parallel limitations tied specifically to alopecia areata
28	At least 97% deuterium incorporation for claim 27
29	Tablet formulation for claim 28

The claim set contains substantial overlap. For example, the 8 mg twice-daily alopecia areata regimen can be captured through multiple paths:

Claim 2 plus claims 6 and 7;
Claim 2 plus claims 18 and 19;
Claim 27;
Claim 27 plus claim 28;
Claim 27 plus claims 28 and 29 when administered as a tablet.

This redundancy improves litigation coverage if one claim is narrowed, invalidated, or construed restrictively.

What is the strongest commercial claim?

Claim 27 is the strongest commercial claim because it tracks the approved product’s core prescribing regimen.

A commercial product would likely fall within claim 27 if it has all of the following characteristics:

Requirement	Leqselvi-aligned implementation
Disease	Alopecia areata
Route	Oral
Dose	8 mg twice daily
Total dose	16 mg daily
Salt	Deuruxolitinib phosphate
Deuterium content	At least 95% at each designated position

Claim 29 adds the tablet limitation and is particularly relevant to a generic tablet applicant. Claims 28 and 29 require at least 97% deuterium incorporation, creating a higher-purity fallback position.

The principal limitation for enforcement is that these are method claims. Infringement depends on the accused product being used, prescribed, labeled, promoted, or otherwise directed for the claimed treatment. A generic applicant could attempt to avoid liability through a restricted label, although that strategy would be difficult if the product’s only commercially meaningful use is alopecia areata.

What formulations are protected?

The patent protects tablet use through dependent claims 4, 16, and 29. The patent does not, based on the supplied claims, require a particular excipient system, release profile, coating, particle size, or manufacturing process.

The formulation protection is therefore functional rather than compositionally detailed:

Any tablet containing the claimed compound or salt can potentially satisfy the tablet limitations;
The tablet need not be shown to have a specific dissolution profile;
The claims do not appear limited to immediate-release or extended-release technology;
The claims do not require a particular tablet strength, although the 8 mg twice-daily regimen makes 8 mg tablets commercially relevant.

Claims 9 through 14 and 21 through 26 protect oral phosphate-salt administration. These claims may capture the active pharmaceutical ingredient regardless of whether the final dosage form is a tablet, unless a specific tablet limitation is added.

How does the 95% deuterium limitation affect infringement?

The claims require at least 95% deuterium incorporation at every position designated as deuterium. Some claims require at least 97%.

This limitation has two consequences.

First, a product cannot avoid the patent merely because it contains a small proportion of non-deuterated material. If each designated position meets the applicable threshold, the claim limitation is satisfied.

Second, the threshold is assessed position by position, not simply as an average across the molecule. A product with an average deuterium content above 95% could still fall outside a claim if one specifically designated position does not meet the required threshold.

The 97% claims create narrower but potentially useful protection against products manufactured to high isotopic purity. They also create a factual issue for infringement analysis because batch specifications, certificates of analysis, and analytical methods may become relevant.

What is the patent term and expected expiration?

US Patent No. 12,076,323 issued on August 27, 2024. Its enforceable term is generally governed by the earliest effective nonprovisional priority date in the patent family, not by the issue date. The expected expiration is therefore determined by the family’s priority chain, subject to patent-term adjustment and any applicable terminal disclaimer.

For commercial planning, the patent should be treated as a late-2030s barrier unless the term is shortened by a terminal disclaimer, invalidity ruling, or enforceability ruling. Patent-term adjustment can extend the nominal 20-year term, while patent-term extension under 35 U.S.C. § 156 is generally tied to regulatory review and must be confirmed from the patent and FDA records.

The issuance date does not mean exclusivity begins in 2024. Method claims became enforceable upon issuance, while earlier related patents may have provided overlapping protection before that date.

What is the FDA regulatory and Orange Book status?

FDA approved Leqselvi, deuruxolitinib tablets, in July 2024 for adults and adolescents 12 years and older with severe alopecia areata.[1] The approved dosage is 8 mg twice daily, matching claim 27.

The product is a small-molecule drug approved through an NDA, not a biologic. Biosimilar provisions therefore do not apply. A future competitor would ordinarily use the ANDA pathway, a 505(b)(2) application, or a full NDA depending on the proposed product and labeling.

Orange Book relevance depends on whether the patent is listed against the approved NDA and whether the listed patent claims the drug, an approved method of use, or both. Method-of-use patents can generate a Paragraph IV certification if listed and if an ANDA applicant seeks approval before patent expiration. A Section viii statement may be available for a carve-out of the patented indication, but that route would be commercially difficult where alopecia areata is the principal approved use.

The NDA holder’s patent listing strategy is likely to rely on:

The approved 8 mg twice-daily regimen;
Deuruxolitinib phosphate;
Alopecia areata treatment;
Tablet administration;
Related formulation or manufacturing patents in the family.

Are there known Paragraph IV challenges?

The supplied information does not establish a filed Paragraph IV certification, ANDA litigation complaint, or settlement involving US Patent No. 12,076,323.

Because Leqselvi was approved in 2024, a generic challenge would be expected to focus on:

Invalidity based on obviousness;
Written-description or enablement arguments concerning deuterium purity and dosing;
Anticipation by earlier ruxolitinib or deuterated JAK-inhibitor disclosures;
Noninfringement through a label carve-out;
The distinction between the claimed phosphate salt and alternative salts or free-base products.

A Paragraph IV notice would expose the NDA holder to a potential 30-month stay under the Hatch-Waxman Act if the relevant patent were properly listed and litigation were filed within the statutory period.

No biosimilar challenge is expected because deuruxolitinib is a chemically synthesized small molecule.

How strong is the patent estate?

The patent estate is commercially meaningful but structurally different from a classic composition-of-matter estate.

Strengths

Claim 27 closely matches the approved 8 mg twice-daily regimen.
The claims cover the phosphate salt used in the commercial product.
The claim set includes both broad 95% and narrower 97% deuterium thresholds.
Multiple dependent claims duplicate the principal commercial limitations.
The approved indication, route, dose, salt, and dosage form align with the claims.

Vulnerabilities

The patent is primarily method-of-use based.
The compound is a deuterated derivative of the known JAK inhibitor ruxolitinib.
Obviousness arguments may focus on prior deuterated analogs, routine isotope substitution, and clinical dose selection.
A generic applicant may attempt a label carve-out or use a different salt or formulation.
Enforcement requires proof connecting the accused product to the claimed method.

The estate is strongest against a direct copy of Leqselvi. It is weaker against a competitor that uses a different salt, different dosing schedule, different formulation, or a non-alopecia indication, assuming related patents do not cover those alternatives.

What generic entry risks exist?

Scenario 1: Direct 8 mg twice-daily copy

This is the highest-risk scenario for a generic applicant. The product would likely implicate claim 27 and dependent claims 28 and 29 if it uses the phosphate salt, high deuterium incorporation, and tablet form.

Scenario 2: Alternative salt

An alternative pharmaceutically acceptable salt could avoid claims requiring the phosphate salt, but it would not necessarily avoid claim 1 or other claims covering a pharmaceutically acceptable salt at 16 mg per day.

Scenario 3: Different dosing schedule

A once-daily 16 mg product could avoid claims requiring twice-daily administration but remain within claim 1 and claims 5, 10, or 13 if the applicable salt and dosing limitations are met.

Scenario 4: Label carve-out

A generic applicant could seek approval without an alopecia areata indication. This strategy is commercially limited if alopecia areata is the only meaningful market for deuruxolitinib.

Scenario 5: Non-tablet oral product

A capsule or other oral dosage form might avoid tablet-specific claims but could remain exposed to the broader oral, phosphate-salt, dose, and alopecia areata claims.

How does deuruxolitinib compare with competing alopecia areata drugs?

Product	Active ingredient	Company	Approved use	Key dose	Patent risk profile
Leqselvi	Deuruxolitinib	Sun Pharma	Severe alopecia areata	8 mg twice daily	Method-of-use, salt, formulation, and related family claims
Litfulo	Ritlecitinib	Pfizer	Severe alopecia areata	50 mg once daily	Separate composition, formulation, and method claims
Olumiant	Baricitinib	Eli Lilly	Alopecia areata and other indications	Dose varies by indication	Older JAK-inhibitor estate with indication-specific claims
Cibinqo	Abrocitinib	Pfizer	Atopic dermatitis	Dose varies	Competing JAK inhibitor, not an interchangeable alopecia product

Leqselvi and Litfulo compete clinically but have separate active ingredients and patent estates. A generic ritlecitinib challenge would not directly resolve deuruxolitinib patent issues.

What licensing and ownership issues affect the estate?

Concert Pharmaceuticals developed CTP-543 and was acquired by Sun Pharmaceutical Industries in 2023. The acquisition transferred the commercial program and associated intellectual-property interests to Sun Pharma.[2]

The ownership history matters because:

Assignment records determine the current patent owner;
NDA and patent-listing responsibilities may sit with different affiliated entities;
Licensing or acquisition agreements may contain field-of-use, royalty, or prosecution provisions;
Patent enforcement standing depends on the recorded chain of title.

No separate third-party license is established by the supplied claims. The commercial rights should be analyzed through USPTO assignment records, SEC transaction filings, and the NDA ownership record.

Key Takeaways

US Patent 12,076,323 protects methods of treating hair-loss disorders with 16 mg per day of deuruxolitinib or a pharmaceutically acceptable salt.
Claim 27 is the principal commercial claim because it covers oral 8 mg twice-daily phosphate-salt treatment of alopecia areata.
Claims 28 and 29 add 97% deuterium incorporation and tablet administration.
The patent is a method-of-use patent, not merely a molecule patent.
Leqselvi’s approved regimen closely matches the patent claims.
The highest generic risk involves a direct copy using deuruxolitinib phosphate tablets at 8 mg twice daily.
Alternative salts, formulations, dosing schedules, and label carve-outs may reduce exposure but do not automatically avoid the broader claims.
Biosimilar litigation is not relevant because deuruxolitinib is a small-molecule drug.
The patent should be evaluated together with related composition, formulation, manufacturing, and method patents in the deuruxolitinib family.
The estate is commercially strong against direct Leqselvi substitution but more vulnerable to design-around strategies and obviousness challenges.

FAQs

Does US Patent 12,076,323 cover ruxolitinib?

No. The claims identify a deuterated compound. Ordinary non-deuterated ruxolitinib would not satisfy the claimed deuterium-incorporation limitations.

Can a generic avoid the patent by using a capsule instead of a tablet?

A capsule may avoid tablet-specific claims such as claim 29, but it may still infringe broader claims covering oral administration, the phosphate salt, alopecia areata, and the 16 mg daily dose.

Does a 16 mg once-daily product avoid claim 27?

Potentially, because claim 27 requires 8 mg twice daily. It may still fall within claim 1 or other claims that cover 16 mg per day without requiring twice-daily administration.

Is a different deuruxolitinib salt outside the patent?

A different salt may avoid claims specifically requiring the phosphate salt. It may remain within claims covering a pharmaceutically acceptable salt generally.

What is the principal invalidity issue?

The principal issue is likely obviousness based on prior disclosures of ruxolitinib, deuterated JAK inhibitors, isotope substitution, and treatment of alopecia areata, combined with the claimed dose and salt selection.

References

U.S. Food and Drug Administration. (2024). Leqselvi (deuruxolitinib) prescribing information.
Sun Pharmaceutical Industries Limited. (2023). Sun Pharma completes acquisition of Concert Pharmaceuticals.
United States Patent and Trademark Office. (2024). U.S. Patent No. 12,076,323, methods of treating hair loss disorders.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Code, 35 U.S.C. §§ 271, 271(e), 156.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes	12,076,323	⤷ Start Trial				TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017261286	⤷ Start Trial
Australia	2023201112	⤷ Start Trial
Australia	2025213576	⤷ Start Trial
Brazil	112018072339	⤷ Start Trial
Canada	3022519	⤷ Start Trial
China	109069493	⤷ Start Trial
China	121868312	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,076,323

Which drugs does patent 12,076,323 protect, and when does it expire?

Summary for Patent: 12,076,323